Charles Schwab Investment Management Inc. Sells 7,214 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Supernus Pharmaceuticals by 1.0%, owning approximately $24.44 million worth of shares after selling 7,214 shares in the first quarter.
• CEO Jack A. Khattar sold 140,000 shares at an average price of $42.02, decreasing his ownership by nearly 12%, while insiders have sold a total of 152,826 shares in the last three months.
• Supernus Pharmaceuticals received an upgrade to a buy rating from Wall Street Zen, with a consensus rating of "Moderate Buy" and an average price target of $41.00.

Charles Schwab Investment Management Inc. decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 1.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 746,149 shares of the specialty pharmaceutical company's stock after selling 7,214 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.33% of Supernus Pharmaceuticals worth $24,436,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Supernus Pharmaceuticals by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after acquiring an additional 1,083 shares during the period. Two Sigma Advisers LP raised its holdings in Supernus Pharmaceuticals by 14.7% during the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after purchasing an additional 1,000 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after acquiring an additional 9,590 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock worth $2,169,000 after purchasing an additional 3,495 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Supernus Pharmaceuticals by 63.6% during the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock worth $579,000 after acquiring an additional 6,867 shares during the last quarter.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 7,457 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the sale, the director owned 46,307 shares in the company, valued at approximately $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the completion of the sale, the chief financial officer directly owned 1,246 shares in the company, valued at approximately $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 164,606 shares of company stock worth $6,948,865. Company insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ SUPN traded down $0.11 during midday trading on Tuesday, hitting $44.32. 372,839 shares of the company's stock were exchanged, compared to its average volume of 1,088,015. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60. The company has a market cap of $2.49 billion, a price-to-earnings ratio of 38.54 and a beta of 0.74. The business's fifty day moving average price is $35.88 and its two-hundred day moving average price is $33.77.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent analyst reports. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, Supernus Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $41.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.